ANTIPODES PARTNERS Ltd cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.9% in the first quarter, HoldingsChannel reports. The firm owned 1,394,971 shares of the biopharmaceutical company’s stock after selling 304,953 shares during the period. Gilead Sciences comprises about 4.5% of ANTIPODES PARTNERS Ltd’s investment portfolio, making the stock its 11th largest holding. ANTIPODES PARTNERS Ltd’s holdings in Gilead Sciences were worth $90,687,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Park Avenue Securities LLC bought a new stake in Gilead Sciences during the 1st quarter valued at $212,000. Buckingham Asset Management LLC raised its position in Gilead Sciences by 1,038.5% during the 1st quarter. Buckingham Asset Management LLC now owns 44,377 shares of the biopharmaceutical company’s stock valued at $2,885,000 after purchasing an additional 40,479 shares in the last quarter. PICTET BANK & TRUST Ltd bought a new stake in Gilead Sciences during the 1st quarter valued at $260,000. ARGA Investment Management LP raised its position in Gilead Sciences by 16.5% during the 1st quarter. ARGA Investment Management LP now owns 42,104 shares of the biopharmaceutical company’s stock valued at $2,737,000 after purchasing an additional 5,975 shares in the last quarter. Finally, Vision Capital Management Inc. increased its holdings in shares of Gilead Sciences by 9.7% in the 1st quarter. Vision Capital Management Inc. now owns 43,656 shares of the biopharmaceutical company’s stock valued at $2,838,000 after acquiring an additional 3,866 shares during the period. 79.94% of the stock is owned by institutional investors and hedge funds.
In related news, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the transaction, the director now directly owns 34,669 shares in the company, valued at approximately $2,270,126.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $62.61, for a total value of $169,047.00. Following the transaction, the director now owns 57,560 shares in the company, valued at $3,603,831.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,670 shares of company stock worth $3,142,526. 0.20% of the stock is owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The firm had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the business earned $1.48 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 annualized dividend and a yield of 3.86%. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.
GILD has been the topic of a number of analyst reports. Mizuho set a $88.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Monday, April 22nd. Wells Fargo & Co downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price target for the company from $95.00 to $68.00 in a report on Monday, February 11th. Oppenheimer set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Monday, April 22nd. Citigroup reiterated a “buy” rating and issued a $100.00 price target on shares of Gilead Sciences in a report on Tuesday, February 5th. Finally, Raymond James set a $83.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Friday, May 3rd. Nine analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $81.61.
TRADEMARK VIOLATION NOTICE: This story was first reported by WKRB News and is the property of of WKRB News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.wkrb13.com/2019/05/16/gilead-sciences-inc-gild-shares-sold-by-antipodes-partners-ltd.html.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Recommended Story: How Do I Invest in Dividend Stocks
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.